logo-loader
viewNetscientific PLC

NetScientific rockets as ProAxsis sees positive early trial data for NEATstik lung disease test

The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes

Lungs
NetScientific holds a 56.5% stake in ProAxsis

NetScientific PLC (LON:NSCI) shares soared on Friday after its portfolio firm, ProAxsis, received positive early data from a clinical trial of its NEATstik lung disease test.

The AIM-listed firm, which commercialises healthcare IPs and holds a 56.5% stake in ProAxsis, said the data had come from BRIDGE, a major three-year study into bronchiectasis, a condition that causes abnormal widening of the lungs, involving over 1000 patients and funded by the British Lung Foundation and the European Respiratory Society.

READ: NetScientific to focus on extending lifespan as CEO reiterates confidence in portfolio firms

The data, published in the peer-reviewed European Respiratory Journal, found that NEATstik was able to replicate the results of existing tests for chest infections within only ten minutes, meaning the test could potentially support appropriate usage of antibiotic therapy.

"This encouraging data published in the renowned European Respiratory Journal demonstrates ProAxsis' ability to monitor bacterial infections in real time in patients suffering from lung diseases”, said Ian Postlethwaite, chief executive of NetScientific.

“NEATstik has the potential to provide clinicians with a test identifying those at risk of further exacerbations providing more targeted care. We believe that ProAxsis has the potential to become a significant player in the growing point-of-care respiratory testing market."

In early deals, NetScientific shares were up 52.7% at 13p.

--Adds share price--

Quick facts: Netscientific PLC

Price: 5.5 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read